Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted ...Middle East

BEIJING, SHANGHAI and BOSTON, July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in...

Read More Details
Finally We wish PressBee provided you with enough information of ( Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted )

Also on site :

• Legendary Rocker, 84, Says He Still Feels 24
• Tesla driver, 22, accused of ramming motorcyclist from Chula Vista, killing him
• Are Your Kids Obsessed with 'KPop Demon Hunters'? Here's Exactly Where to Get the Merch